Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results ; volume:9 ; number:1 ; day:28 ; month:11 ; year:2019 ; pages:1-10 ; date:12.2019
EJNMMI Research ; 9, Heft 1 (28.11.2019), 1-10, 12.2019
- Creator
-
Khawar, Ambreen
Eppard, Elisabeth
Roesch, Frank
Ahmadzadehfar, Hojjat
Kürpig, Stefan
Meisenheimer, Michael
Gaertner, Florian. C.
Essler, Markus
Bundschuh, Ralph. A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-019-0566-x
- URN
-
urn:nbn:de:101:1-2020032322015763169866
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Khawar, Ambreen
- Eppard, Elisabeth
- Roesch, Frank
- Ahmadzadehfar, Hojjat
- Kürpig, Stefan
- Meisenheimer, Michael
- Gaertner, Florian. C.
- Essler, Markus
- Bundschuh, Ralph. A.
- SpringerLink (Online service)
Other Objects (12)
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
Hematopoietic islands mimicking osteoblastic metastases within the axial skeleton
New Theranostic Radionuclides for Metastatic Bone Disease : Biodistribution and Dosimetric Analysis
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
125I brachytherapy: a useful treatment to control painful osteoblastic bone metastases
177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
Diffusion-Weighted MRI for Treatment Response Assessment in Osteoblastic Metastases—A Repeatability Study
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Prognostic analysis of percutaneous vertebroplasty (PVP) combined with 125I implantation on lumbosacral vertebral osteoblastic metastases
Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile
Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
Hematopoietic islands mimicking osteoblastic metastases within the axial skeleton
New Theranostic Radionuclides for Metastatic Bone Disease : Biodistribution and Dosimetric Analysis
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
125I brachytherapy: a useful treatment to control painful osteoblastic bone metastases
177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
Diffusion-Weighted MRI for Treatment Response Assessment in Osteoblastic Metastases—A Repeatability Study
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Prognostic analysis of percutaneous vertebroplasty (PVP) combined with 125I implantation on lumbosacral vertebral osteoblastic metastases
Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile
Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
Hematopoietic islands mimicking osteoblastic metastases within the axial skeleton
New Theranostic Radionuclides for Metastatic Bone Disease : Biodistribution and Dosimetric Analysis
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
125I brachytherapy: a useful treatment to control painful osteoblastic bone metastases
177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
Diffusion-Weighted MRI for Treatment Response Assessment in Osteoblastic Metastases—A Repeatability Study
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Prognostic analysis of percutaneous vertebroplasty (PVP) combined with 125I implantation on lumbosacral vertebral osteoblastic metastases
Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile
Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment